Hormone tests for women over 40 can clarify what's behind symptoms like cycle changes, fatigue, sleep disruption, and mood shifts. Depending on age, menstrual status, and medical history, a targeted blood panel may include FSH, estradiol, thyroid markers, and metabolic indicators. Major clinical guidelines from ACOG and the European Society of Endocrinology agree that not every woman over 40 needs routine hormone testing, but they also identify specific situations where a blood draw provides information that a symptom history alone can't. The right lab panel, ordered at the right time, gives a provider something concrete to interpret.
Marek Diagnostics offers direct-access lab testing with panels designed for women at different stages of the reproductive transition. Results are processed through Quest Diagnostics locations across the U.S., and most are available within 14 business days.
What Are Hormone Tests for Women Over 40?
A hormone test for women over 40 is a blood draw that measures reproductive and metabolic markers tied to the perimenopausal and menopausal transition. The most commonly ordered markers are follicle-stimulating hormone (FSH), estradiol (E2), thyroid-stimulating hormone (TSH), and progesterone. Some panels add anti-Mullerian hormone (AMH), sex hormone-binding globulin (SHBG), testosterone, luteinizing hormone (LH), and prolactin.
These tests exist to answer specific questions a provider can't settle from symptoms alone. Is this fatigue from a thyroid problem or from shifting estradiol levels? Is an irregular cycle a sign of perimenopause or a condition like polycystic ovary syndrome? Has FSH risen enough to suggest the ovaries are winding down? A provider uses the results alongside symptoms and history to narrow the differential.
Does Every Woman Over 40 Need a Hormone Panel?
No. In otherwise healthy women aged 45 or older who have typical perimenopausal symptoms and a changing menstrual pattern, current guidelines say the diagnosis is clinical. A blood test isn't required.
ACOG's September 2025 patient guidance puts it plainly: an ob-gyn can usually tell if a woman is in perimenopause based on age, symptoms, and period changes (ACOG, 2025). The European Society of Endocrinology's 2025 clinical practice guideline, endorsed by the Endocrine Society and others, states that biochemical testing for perimenopause or menopause is not necessary in women older than 45 (ESE, 2025).
Testing becomes useful when the picture is less clear. The same guidelines recommend it for women aged 40-45 with symptoms and cycle changes, and they require it for women under 40 when premature ovarian insufficiency (POI) is suspected. It's also indicated when symptoms overlap with thyroid disease, iron deficiency, or other conditions that mimic hormonal shifts.
Guidelines generally support lab testing at 40-45 when symptoms and cycle changes are present, while clinical diagnosis alone may be sufficient at 45 and older. A provider weighs individual factors, including medical history, medication use, and how well the symptoms fit the expected pattern.
Which Hormones to Test After 40
The markers worth ordering depend on the question being asked. Not every woman needs a 100-biomarker panel. A targeted draw often provides more useful information.
FSH. The primary marker guidelines use when blood testing is indicated. FSH rises as ovarian reserve declines, but it fluctuates during the transition. NICE NG23 (updated 2024) recommends considering serum FSH in women aged 40-45 with symptoms and menstrual change, and requires two draws 4-6 weeks apart for POI evaluation in women under 40 (NICE, 2024). Ordering an FSH and LH panel together may give a provider more context about pituitary signaling.
Estradiol. The main circulating estrogen. Interpreted alongside FSH, not in isolation. The International Menopause Society's 2025 recommendations note that routine measurement of serum estradiol to set a hormone therapy dose is generally not recommended, but estradiol measurement may help when symptom relief is poor, side effects persist, or in POI and early menopause (IMS, 2025). Marek offers standard estradiol and a sensitive LC/MS-MS assay for lower ranges.
TSH. Thyroid dysfunction and perimenopause share symptoms: fatigue, weight change, mood shifts, palpitations. A TSH draw is often among the most clinically useful tests for a woman over 40 whose complaints overlap with thyroid dysfunction. This individual biomarker can be added to any panel.
Progesterone. Useful in selected cycle evaluations. A luteal-phase progesterone draw can support evidence of ovulation, which becomes irregular during the late reproductive stage.
AMH. Anti-Mullerian hormone reflects granulosa-cell reserve. The FDA cleared an AMH assay (picoAMH) in 2018 as an aid in determining menopausal status in women aged 42-62, used alongside other clinical findings (FDA, 2018). ACOG Committee Opinion 773 takes a different position: AMH should not be used to predict menopause timing in routine practice and should not be ordered to counsel non-infertile women about future fertility (ACOG, 2019). AMH is an adjunct data point, not a date-stamp.
TSH, ferritin, and metabolic markers. The look-alike list is long. Iron deficiency causes fatigue, hair thinning, and poor concentration. Insulin resistance contributes to weight shifts and irregular cycles. Adding a ferritin test, fasting insulin, and HbA1c to a hormone draw gives a provider a wider picture with one blood sample.
Why a Single FSH Draw Is Often Misleading
One of the largest longitudinal studies of the menopausal transition, the Study of Women's Health Across the Nation (SWAN), documented how FSH and estradiol behave across the years surrounding the final menstrual period (FMP). FSH began rising a mean of 6.10 years before the FMP, accelerated about 2 years before, and stabilized approximately 2 years after (Randolph et al., 2011). That's a long, uneven ramp, not a clean switch.
Estradiol followed 4 distinct trajectories in SWAN, not 1 smooth decline: rise then steep decline (31.5%), rise then slow decline (13.1%), slow decline (26.9%), and flat or limited decline (28.6%) (Tepper et al., 2012). Obesity and race/ethnicity influenced which path a woman followed. A single blood draw cannot place a woman on one of these curves.
This is why guidelines use menstrual pattern as the primary staging tool (STRAW+10) and treat FSH as a supportive criterion. A "normal" FSH doesn't rule out perimenopause. A "high" FSH doesn't prove the last period has happened. For women under 45 or those being evaluated for POI, two draws spaced 4-6 weeks apart, interpreted alongside the clinical picture, are the guideline standard.
Timing, Cycle Day, and Contraception
When blood is drawn matters. FSH and estradiol are most informative on cycle days 2-5 or after more than 40 days without a period, per the ESE 2025 guideline (ESE, 2025). A random-day draw during mid-cycle can produce misleading numbers.
Women on combined hormonal contraception (pill, patch, ring) present a separate problem. These methods suppress the HPO axis, making FSH and estradiol readings clinically uninformative for menopausal staging. NICE NG23 explicitly says not to use FSH to identify menopause in women using combined estrogen-progestogen contraception or high-dose progestogen (NICE, 2024). A provider may recommend stopping the method for a washout period before ordering labs, or switching to a non-hormonal option first.
Progestogen-only methods (hormonal IUD, mini-pill) don't suppress FSH as strongly, but interpretation still requires clinical judgment.
How Testing Approaches Compare
|
Approach |
What it measures |
When guidelines call it useful after 40 |
Main limitation |
|
Clinical history and cycle pattern |
Symptoms, bleeding, age |
First-line at 45+ (NICE, ACOG, ESE, IMS, STRAW+10) |
Can't stage if the uterus is absent or cycles are suppressed |
|
Serum FSH |
Pituitary drive |
Consider at 40-45 with symptoms; required twice (4-6 weeks apart) for POI under 40 |
Fluctuates month to month; uninformative on combined hormonal contraception |
|
Serum estradiol |
Circulating E2 |
Interpret with FSH; may help when treatment response is poor or in POI |
Cycle-day dependent; 4 distinct trajectories in SWAN |
|
AMH |
Granulosa-cell reserve |
Aid to menopausal status ages 42-62 with other findings (FDA 2018 clearance) |
ACOG says don't use to predict menopause timing in routine practice |
|
TSH |
Thyroid function |
When symptoms overlap (fatigue, palpitations, weight, mood) |
Does not diagnose menopause; diagnoses thyroid disease |
|
Saliva or urine steroid panels |
Various hormones |
Not recommended by ACOG for prescribing or dosing hormone therapy |
No FDA-approved salivary or urinary test for this use; limited data |
ACOG's 2023 clinical consensus on compounded bioidentical hormone therapy noted that adjunct hormone tests (saliva, serum, urine) are not recommended for dosing compounded formulations (ACOG, 2023). If a provider recommends a saliva panel to "map" hormone levels and customize a compound, that falls outside current society guidance.
What Results Mean and What to Do Next
Lab results don't diagnose perimenopause by themselves. They provide data that a provider interprets alongside age, symptoms, cycle history, medications, and the differential diagnosis. An elevated FSH, interpreted against the assay's own reference range, can support a clinical impression of perimenopause or menopause when the rest of the picture lines up. The number alone isn't a verdict.
The Menopause Society's 2022 hormone therapy position statement describes the benefit-risk framework for treatment decisions: for healthy symptomatic women under 60 or within 10 years of menopause onset and without contraindications, the benefit-risk balance for hormone therapy is favorable for bothersome vasomotor symptoms and bone loss prevention (Faubion et al., 2022). That decision happens between a client and a licensed provider, not from a lab printout.
After reviewing results, a provider may recommend repeat testing, additional markers, imaging (mammography, bone density, pelvic ultrasound through a separate order), or treatment. Results that show an unexpected pattern, like elevated prolactin or suppressed TSH, point to conditions that need further workup before any hormone-related treatment.
How to Order Hormone Testing
Marek Diagnostics offers women's lab panels built for the perimenopausal and menopausal stages, including the Perimenopause Panel, the Menopause Roadmap, and the Menopause Longevity panel. Each bundles the relevant biomarkers at different levels of depth.
Women who already know which markers they need can build a custom panel from over 100 individual biomarkers and order only what's relevant to their situation. Hormone tests for women over 40 are HSA/FSA eligible and processed at over 2,000 Quest Diagnostics locations nationwide. Results are typically available within 14 business days. Review them with a provider for clinical interpretation and next steps.
Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.
FAQs
Can a hormone test tell me if I am in perimenopause?
For healthy women 45 and older with typical symptoms and cycle changes, ACOG and the ESE say a blood test isn't required for diagnosis. FSH rises and falls during the transition. SWAN showed FSH starting to climb about 6 years before the final menstrual period, so one value is a snapshot, not a stage. A provider can usually identify perimenopause from symptoms and menstrual history alone.
What FSH level means menopause?
There is no single universal cutoff. Guidelines use different FSH thresholds, and values vary by assay and lab. For POI evaluation, most guidelines require 2 elevated readings taken 4-6 weeks apart. Menopause itself is defined as 12 consecutive months without a period, not by a lab number. A provider interprets results in context.
Should I test hormones while I am on birth control?
Combined hormonal contraception (pill, patch, ring) suppresses the HPO axis. NICE NG23 says not to use FSH to identify menopause in women using combined estrogen-progestogen methods. A provider may recommend stopping the method or switching to a non-hormonal option before ordering labs.
Is AMH a better menopause test than FSH?
The FDA cleared an AMH assay in 2018 as an aid in determining menopausal status for women aged 42-62, used with other findings. ACOG Committee Opinion 773 takes a different position, stating that AMH is not suitable for predicting menopause onset in routine practice. AMH can add information, but it doesn't replace menstrual history or clinical evaluation.
Do I need saliva or urine hormone testing?
ACOG's 2023 clinical consensus states that no FDA-approved salivary or urinary tests exist for hormone measurement in this setting, and adjunct tests aren't recommended for prescribing or dosing hormone therapy. Serum blood testing remains the standard when lab data is needed.
Should women over 40 have their testosterone checked?
The Endocrine Society's 2014 guideline recommends against diagnosing an "androgen deficiency syndrome" in healthy women, because testosterone levels don't map cleanly onto symptoms. The 2019 Global Consensus Position Statement identifies only one evidence-based indication for testosterone in women: postmenopausal hypoactive sexual desire disorder (HSDD), after a biopsychosocial assessment. There is no FDA-approved testosterone product for women in the U.S.
How do I order hormone tests for women over 40 through Marek Diagnostics?
Select a pre-built panel (Perimenopause Panel, Menopause Roadmap, or Menopause Longevity) or build a custom panel from individual biomarkers. Place the order, visit a Quest Diagnostics location to give a blood sample, and receive results within 14 business days. Review them with a provider for interpretation and next steps.
References
Share:
Can You Get A Hormone Test On Your Period? What To Know